Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells $287,625.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 12,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $23.01, for a total value of $287,625.00. Following the transaction, the chief operating officer directly owned 196,141 shares in the company, valued at approximately $4,513,204.41. This represents a 5.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Monday, March 16th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $19.66, for a total value of $245,750.00.
• On Tuesday, March 3rd, Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.16, for a total value of $315,838.72.
• On Thursday, January 22nd, Ryan Cohlhepp sold 3,828 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.10, for a total value of $69,286.80.

Bicara Therapeutics Stock Performance

BCAX opened at $24.01 on Monday. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -9.49 and a beta of -1.23. The stock’s 50 day moving average price is $18.65 and its 200-day moving average price is $17.59. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $24.25.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.04. As a group, analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on BCAX shares. Wells Fargo & Company increased their price objective on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 31st. The Goldman Sachs Group increased their price objective on Bicara Therapeutics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Citigroup started coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating on the stock. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Finally, UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Eight analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $28.00.

Institutional Trading of Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bleakley Financial Group LLC bought a new stake in Bicara Therapeutics during the 3rd quarter valued at $481,000. Cantor Fitzgerald L. P. bought a new stake in Bicara Therapeutics during the 3rd quarter valued at $1,579,000. Nan Fung Trinity HK Ltd. boosted its position in Bicara Therapeutics by 12.2% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 384,885 shares of the company’s stock valued at $6,077,000 after acquiring an additional 42,000 shares in the last quarter. Cinctive Capital Management LP bought a new stake in Bicara Therapeutics during the 3rd quarter valued at $661,000. Finally, Atle Fund Management AB boosted its position in Bicara Therapeutics by 38.3% during the 3rd quarter. Atle Fund Management AB now owns 203,755 shares of the company’s stock valued at $3,217,000 after acquiring an additional 56,375 shares in the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.